

### **Amendment to the Claims**

The listing of claims will replace all prior versions, and listings, of claims in this application.

1. (original) A drug eluting medical device comprising:  
an implantable intraluminal structure;  
a pharmaceutically active agent, in therapeutic dosages, affixed to at least a portion of the implantable intraluminal structure; and  
a stabilizing agent mixed with the pharmaceutically active agent to substantially hinder degradation thereof through oxidation.
2. (original) The drug eluting medical device according to claim 1, wherein the implantable intraluminal structure comprises a stent.
3. (original) The drug eluting medical device according to claim 1, wherein the pharmaceutically active agent comprises a rapamycin.
4. (original) The drug eluting medical device according to claim 1, wherein the pharmaceutically active agent comprises sirolimus.
5. (original) The drug eluting medical device according to claim 1, wherein the stabilizing agent comprises an antioxidant.
6. (original) The drug eluting medical device according to claim 5, wherein the antioxidant comprises Butylated Hydroxytoluene.
7. (original) The drug eluting medical device according to claim 5, wherein the antioxidant comprises Tocopherols.
8. (original) The drug eluting medical device according to claim 5, wherein the antioxidant comprises Ascorbic Acid.

9. (original) The drug eluting medical device according to claim 5, wherein the antioxidant comprises Ascorbyl Palmitate.

10. (original) A drug eluting medical device comprising:

an implantable intraluminal structure;

a polymeric solution;

a pharmaceutically active agent, in therapeutic dosages, incorporated into the polymeric solution, the resulting mixture being affixed to at least a portion of the implantable intraluminal structure; and

a stabilizing agent incorporated into the resulting mixture to substantially hinder degradation of the pharmaceutically active agent through oxidation.

11. (original) The drug eluting medical device according to claim 10, wherein the implantable intraluminal structure comprises a stent.

12. (original) The drug eluting medical device according to claim 10, wherein the pharmaceutically active agent comprises a rapamycin.

13. (original) The drug eluting medical device according to claim 10, wherein the pharmaceutically active agent comprises sirolimus.

14. (original) The drug eluting medical device according to claim 10, wherein the stabilizing agent comprises an antioxidant.

15. (original) The drug eluting medical device according to claim 14, wherein the antioxidant comprises Butylated Hydroxytoluene.

16. (original) The drug eluting medical device according to claim 14, wherein the antioxidant comprises Tocopherols.

17. (original) The drug eluting medical device according to claim 14, wherein the antioxidant comprises Ascorbic Acid.

18. (original) The drug eluting medical device according to claim 14, wherein the antioxidant comprises Ascorbyl Palmitate.

19. (original) A drug eluting medical device comprising:  
an implantable intraluminal structure;  
a polymeric solution;  
a pharmaceutically active agent, in therapeutic dosages, incorporated into the polymeric solution, the resulting mixture being affixed to at least a portion of the implantable intraluminal structure; and  
a stabilizing agent incorporated into the resulting mixture to substantially hinder degradation of the pharmaceutically active agent through oxidation, the stabilizing agent being incorporated into the resulting mixture such that it is proximate the pharmaceutically active agent.

20. (original) The drug eluting medical device according to claim 19, wherein the implantable intraluminal structure comprises a stent.

21. (original) The drug eluting medical device according to claim 19, wherein the pharmaceutically active agent comprises a rapamycin.

22. (original) The drug eluting medical device according to claim 19, wherein the pharmaceutically active agent comprises sirolimus.

23. (original) The drug eluting medical device according to claim 19, wherein the stabilizing agent comprises an antioxidant.

24. (original) The drug eluting medical device according to claim 23, wherein the antioxidant comprises Butylated Hydroxytoluene.

25. (original) The drug eluting medical device according to claim 23, wherein the antioxidant comprises Tocopherols.

26-33. Cancelled.

34. (original) The drug eluting medical device according to claim 30, wherein the antioxidant comprises Ascorbyl Palmitate in the range from about 0.01 to about 0.02 percent weight by volume.

35. (original) The drug eluting medical device according to claim 30, wherein the antioxidant comprises 250 ppm Butylated Hydroxytoluene.